VATIS UPDATE Article

Researchers at Allele Biotechnology and Pharmaceuticals, the United States, headed by Dr. Jiwu Wang, has persisted in finding what they believe to be the best, safest and most ethical way of administering stem cell therapy beginning with one’s own skin cells. “To have pluripotent stem cells means having a source of cells capable of changing into any type of cell like the lung cells, liver cells neurons, pancreatic beta cells, and so on,” explained Dr. Wang.

From there, Allele’s discovered a more efficient way to reprogram cells since research began in 2009, a process which has since been able to file for multiple patents. Due to its promising results, the research has received funding from the federal government, which has long been very careful in providing assistance to stem cell therapy related research, precisely for the many controversies its kind has raised through the years.

Best of all, Allele’s stem cell therapy is already in the process of generating personalized stem cells under the high standard termed current Good Manufacture Practice, or cGMP, defined by the US Food and Drug Administration (FDA) aimed for application in clinical cell therapy just as they began banking cells from patients in their San Diego laboratories.